NASDAQ
Champions Oncology, Inc. (CSBR)
♥ 625 Thanks from members
Champions Oncology (CSBR) posted record fiscal 2026 revenues of $59.4 million and four consecutive quarters of positive adjusted EBITDA, driven by core Translational Oncology Solutions and internal radiopharmaceutical expansion, though the stock dipped amid GAAP losses and mixed valuation models.